These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 21448811)

  • 1. Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.
    Arevalo JF; Espinoza JV
    Graefes Arch Clin Exp Ophthalmol; 2011 Aug; 249(8):1159-66. PubMed ID: 21448811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Half-Fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy: Predisposing Factors for Visual Acuity Outcomes.
    Matušková V; Vysloužilová D; Uher M
    Semin Ophthalmol; 2018; 33(5):690-699. PubMed ID: 29252091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vascularized retinal pigment epithelial detachment in age-related macular degeneration: treatment and RPE tear incidence.
    Introini U; Torres Gimeno A; Scotti F; Setaccioli M; Giatsidis S; Bandello F
    Graefes Arch Clin Exp Ophthalmol; 2012 Sep; 250(9):1283-92. PubMed ID: 22350060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-fluence photodynamic therapy versus ranibizumab for chronic central serous chorioretinopathy: one-year results of a randomized trial.
    Bae SH; Heo J; Kim C; Kim TW; Shin JY; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Ophthalmology; 2014 Feb; 121(2):558-65. PubMed ID: 24268858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration.
    Lazic R; Gabric N
    Ophthalmology; 2007 Jun; 114(6):1179-85. PubMed ID: 17544776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab (Avastin) in combination with verteporfin photodynamic therapy for choroidal neovascularization associated with age-related macular degeneration (IBeVe Study).
    Costa RA; Jorge R; Calucci D; Melo LA; Cardillo JA; Scott IU
    Graefes Arch Clin Exp Ophthalmol; 2007 Sep; 245(9):1273-80. PubMed ID: 17333238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized pilot study of low-fluence photodynamic therapy versus intravitreal ranibizumab for chronic central serous chorioretinopathy.
    Bae SH; Heo JW; Kim C; Kim TW; Lee JY; Song SJ; Park TK; Moon SW; Chung H
    Am J Ophthalmol; 2011 Nov; 152(5):784-92.e2. PubMed ID: 21742303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results of low-fluence photodynamic therapy for chronic central serous chorioretinopathy.
    Leys E; Tuttle S; Rasquin F; Neu F; Postelmans L
    J Fr Ophtalmol; 2015 Oct; 38(8):709-16. PubMed ID: 26345542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Yellow (577 nm) micropulse laser versus half-dose verteporfin photodynamic therapy in eyes with chronic central serous chorioretinopathy: results of the Pan-American Collaborative Retina Study (PACORES) Group.
    Roca JA; Wu L; Fromow-Guerra J; Rodríguez FJ; Berrocal MH; Rojas S; Lima LH; Gallego-Pinazo R; Chhablani J; Arevalo JF; Lozano-Rechy D; Serrano M
    Br J Ophthalmol; 2018 Dec; 102(12):1696-1700. PubMed ID: 29439089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Collaborative retrospective macula society study of photodynamic therapy for chronic central serous chorioretinopathy.
    Lim JI; Glassman AR; Aiello LP; Chakravarthy U; Flaxel CJ; Spaide RF;
    Ophthalmology; 2014 May; 121(5):1073-8. PubMed ID: 24439758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-year outcomes with half-dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
    Fujita K; Imamura Y; Shinoda K; Matsumoto CS; Mizutani Y; Hashizume K; Mizota A; Yuzawa M
    Ophthalmology; 2015 Mar; 122(3):555-61. PubMed ID: 25444637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal anti-vascular endothelial growth factor therapy versus photodynamic therapy for idiopathic choroidal neovascularization.
    Kang HM; Koh HJ
    Am J Ophthalmol; 2013 Apr; 155(4):713-9, 719.e1. PubMed ID: 23219069
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Half-fluence photodynamic therapy in chronic central serous chorioretinopathy.
    Smretschnig E; Ansari-Shahrezaei S; Hagen S; Glittenberg C; Krebs I; Binder S
    Retina; 2013 Feb; 33(2):316-23. PubMed ID: 23314238
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Retinochoroidal Vascular and Structural Changes after Half-Dose Photodynamic Therapy versus Half-Fluence Photodynamic Therapy Based on Optical Coherence Tomography Angiography in Eyes with Chronic Central Serous Chorioretinopathy.
    Karasu B; Akbas YB; Aykut A; Celebi ARC
    Ophthalmologica; 2022; 245(4):323-334. PubMed ID: 35249031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY VERSUS PHOTODYNAMIC THERAPY IN THE TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO CENTRAL SEROUS CHORIORETINOPATHY.
    Peiretti E; Caminiti G; Serra R; Querques L; Pertile R; Querques G
    Retina; 2018 Aug; 38(8):1526-1532. PubMed ID: 28699928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravitreal anti-vascular endothelial growth factor combined with half-fluence photodynamic therapy for choroidal neovascularization in chronic central serous chorioretinopathy.
    Smretschnig E; Hagen S; Glittenberg C; Ristl R; Krebs I; Binder S; Ansari-Shahrezaei S
    Eye (Lond); 2016 Jun; 30(6):805-11. PubMed ID: 26965012
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration.
    Forte R; Bonavolontà P; Benayoun Y; Adenis JP; Robert PY
    Ophthalmic Res; 2011; 45(3):129-34. PubMed ID: 20847575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Photodynamic therapy for chronic central serous chorioretinopathy: a 4-year follow-up study.
    Silva RM; Ruiz-Moreno JM; Gomez-Ulla F; Montero JA; Gregório T; Cachulo ML; Pires IA; Cunha-Vaz JG; Murta JN
    Retina; 2013 Feb; 33(2):309-15. PubMed ID: 23095766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy.
    Sheptulin V; Purtskhvanidze K; Roider J
    Graefes Arch Clin Exp Ophthalmol; 2018 Nov; 256(11):2027-2034. PubMed ID: 30097783
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-session photodynamic therapy combined with intravitreal bevacizumab for neovascular age-related macular degeneration.
    Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Ahadi H
    Eur J Ophthalmol; 2008; 18(2):297-300. PubMed ID: 18320527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.